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Summary
Objectives: Human papillomavirus (HPV) infection is a major risk factor for cervical disease.
Using baseline data from the HIV-infected cohort of Evandro Chagas Clinical Research Institute at
Fiocruz, Rio de Janeiro, Brazil, factors associated with an increased prevalence of HPV were
assessed.
Methods: Samples from 634 HIV-infected women were tested for the presence of HPV infection
using hybrid capture II and polymerase chain reaction. Prevalence ratios (PR) were estimated
using Poisson regression analysis with robust variance.
Results: The overall prevalence of HPV infection was 48%, of which 94% were infected with a
high-risk HPV. In multivariate analysis, factors independently associated with infection with high-
risk HPV type were: younger age (<30 years of age; PR 1.5, 95% confidence interval (CI) 1.1—2.1),
current or prior drug use (PR 1.3, 95% CI 1.0—1.6), self-reported history of HPV infection (PR 1.2,
95% CI 0.96—1.6), condom use in the last sexual intercourse (PR 1.3, 95% CI 1.1—1.7), and nadir
CD4+ T-cell count <100 cells/mm3 (PR 1.6, 95% CI 1.2—2.1).* Corresponding author.
E-mail address: gbeatriz@ipec.fiocruz.br (B. Grinsztejn).
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HPV in HIV-infected Brazilian women 73Conclusions: The estimated prevalence of high-risk HPV-infection among HIV-infected women from
Rio de Janeiro, Brazil, was high. Close monitoring of HPV-related effects is warranted in all HIV-
infected women, in particular those of younger age and advanced immunosuppression.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Human papillomavirus (HPV) infection has been consistently
identified as a major risk factor for cervical squamous intrae-
pithelial lesions and invasive cervical cancer.1 In HIV-infected
women, HPV infection and associated cervical diseases are
more prevalent.2—4 One explanation for this finding is HIV-
induced immunosuppression, which may potentiate HPV
replication and progression to cervical squamous intraepithe-
lial lesions.2,5 HIV-infected women are at increased risk of
acquiring HPV infection, show higher HPV prevalence at
subsequent time points, and persistently shed virus.6,7
Finally, the HPV types most frequently associated with cer-
vical cancer, such as HPV 16, are also more prevalent among
HIV-infected women.6
In many developing countries, cervical cancer is the most
common form of cancer in women.8 In Brazil, cervical cancer
is the third most common form of cancer and the fourth cause
of death by cancer.9 Limited cytological screening contri-
butes to the high incidence of cervical cancer. In Brazil, life
expectancy of HIV-infected women has increased with highly
active antiretroviral treatment (HAART) availability.10 We
can speculate that in settings with limited cytological screen-
ing, HIV-infected women may potentially be at greater risk of
developing cervical cancers from persistent cervical squa-
mous intraepithelial lesions. Actually, published data has
shown no clear impact of HAARTon the incidence of cervical
cancers.11,12
Therefore, the accurate assessment of the burden of HIV/
HPV co-infection is of great importance. Data on HPV infec-
tion among HIV-infected women in Brazil are limited. To our
knowledge, few studies have assessed prevalence and risk
factors for HPV among HIV-infected Brazilian women. This
study evaluated the prevalence of HPV infection among HIV-
infected women in Rio de Janeiro, Brazil. Factors associated
with prevalence of high-risk HPV were explored using base-
line data obtained from the HIV-infected cohort of Evandro
Chagas Clinical Research Institute at Fiocruz.13 In addition we
assessed the distribution of specific HPV types in a sub-
sample of the women.
Methods
The cohort of HIV-infected women at the Evandro Chagas
Clinical Research Institute at Fiocruz is a prospective open
cohort followed in a clinical research hospital in Rio de
Janeiro, Brazil. The focus of the cohort is to study the natural
history of HIV infection in women, particularly in women with
HIV/HPV co-infection. The cross-sectional analysis was per-
formed using baseline demographic, behavioral, and epide-
miological data. The baseline HPV infection status was
established from specimens collected at enrollment.
Informed consent was obtained from all women; the study
was approved by the ethics review board of the institution.Cohort procedures have been described elsewhere.13
Briefly, during the initial pelvic examination, samples were
collected in Digene HPV Hybrid Capture Universal Collection
Medium (UCM1) to test for the presence of lower genital
tract infections. Samples for HPV detection were collected,
frozen, and sent to Digene do Brasil (Digene, Inc.).
For all samples, HPV detection and quantification were
assessed using the hybrid capture II method (HC II), a non-
isotopic, signal amplification technique, based on the hybri-
dization of biotinylated RNA probes to the HPV DNA of the
samples. The RNA—DNA hybrids were immobilized in micro-
plate wells using an antibody adsorbed to the well surface. A
cocktail of probes allowed characterization of the HPV posi-
tive samples into low-risk HPV types (group A, including HPV
types 6, 11, 42, 43, and 44) and high-risk HPV types (group B,
including HPV types 16, 18, 31, 33, 35, 39, 45, 51, 53, 56, 58,
59, and 68). HPV viral load results were calculated using a
ratio of relative light units (RLU). The RLU ratio was defined
as the signal generated from the test sample in the presence
of the calibrator compared to the signal generated by 1 pg/
ml of the HPV positive calibrator (PC). Samples that gener-
ated a signal greater than 1 RLU/PC were considered ‘posi-
tive’ for the respective HPV probe mix.
In addition to HC II, cervical samples from the last 112
women enrolled in the cohort were classified according to
HPV type by polymerase chain reaction analysis (PCR). DNA
was extracted using the proteinase K—phenol—chloroform
standard method. Five ml of DNA plus 45 ml of deionized and
distilled water (ddH2O) were added to the linear array HPV
Master Mix (Roche). The mixture contained PCR reagents and
biotinylated primers spanning a 450-bp fragment from HPV L1
gene from 37 HPV genotypes. Human beta-globin biotinylated
primerswerealso includedtocontrol specimencollection,DNA
extraction, and PCR inhibition. Amplification took place in a
gold-plated 9600 thermocycler (Applied Biosystems) and
cycledaccording totheprocedures listed inthepackage insert.
PCR products were denatured and submitted to hybridization
to immobilized oligonucleotide probes specific for each HPV
type,pluscontrolprobes forbeta-globinamplification.Follow-
ing the hybridization and washing steps, the bound amplicons
were identified based on color development via conventional
streptavidin—horseradish peroxidase chemistry. The HPV gen-
otype assessment was performed by comparing each strip
signal to a reference guide provided in the kit. Samples that
displayed an HPV-positive signal but not a beta-globin signal
were excluded from the analysis, while those with no HPV or
beta-globin signalwereconsidered inadequateandnot scored.
CD4+ T-cell count (Becton Dickinson FACScan) results were
obtained from the participant’s medical record; two differ-
ent assessments of immunosuppression were considered. The
nadir CD4+ T-cell count was defined as the lowest level of
immunosuppression reported by the patient since HIV diag-
nosis but prior to entry into the cohort. The baseline CD4+ T-
cell count was defined as the reported level of immunosup-
pression within 90 days of entry in the cohort.
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type, which was determined using the HC II. Since the pre-
valence of high-risk HPV infection was elevated, logistic
regression analysis was not used for the estimation of the
odds ratio.14 A Poisson regression model with robust variance
was used to estimate prevalence ratios for the independent
factors associated with high-risk HPV infection.14—16 Bivari-
ate analysis was performed to assess the association of
variables with high-risk HPV infection. With two exceptions,
all factors independently associated with the outcome in the
bivariate analysis, at the significance level of 0.15, composed
the initial Poisson multivariate model (full model). The
exceptions were ‘baseline CD4+ T-cell count’ and ‘number
of sexual partners within the past year’, which were not
included in the initial Poisson, although the statistical thresh-
old was met. The rationale for these exceptions is related to
the biological significance of these variables. With respect to
the immunodeficiency level of the patient, the nadir CD4+ T-
cell count best represents the level of immunosuppression
reached by the patient, as it is not modified by the antire-
troviral treatment.
Upon entry into the cohort, 53% of the women were
already receiving antiretrovirals (ARV) and this might have
affected their baseline CD4+ T-cell count. Therefore, base-
line CD4+ T-cell count was not included in the initial multi-
variate model. With respect to the ‘number of sexual
partners within the past year’, we considered that the ‘total
number of lifetime sexual partners’ was more realistically
related to the risk of exposure to HPV, as this infection is
usually acquired near the sexual debut. As a result, ‘number
of sexual partners within the past year’ was not included in
the multivariate model. Finally, the variable codifying the
use of HAARTwas forced into the initial Poisson model. The
use of a backwards elimination procedure, with a 5% type I
error acceptance threshold, guided the removal of covariates
until a more parsimonious model was reached. Interactions
between covariates were also explored. The statistical pack-
age STATA 7.0 was used for all analyses.
Results
A total of 634 women were enrolled into the cohort from May
1996 through December 2006. Demographic, behavioral, and
epidemiological data for the cohort are presented in Table 1.
At enrollment, the majority of the women were older than 30
years of age (71%, median age 36 years, interquartile range
29—43 years, mean age 36.3 years, standard deviation 9.6
years) and unmarried/not living with partner (63%). Most
patients were non-white (53%), had received over 8 years of
formal education (41%), and were unemployed (55%). For
those who were employed, the majority earned less than
US$ 300 per month (58%). Approximately 30% of the women
reported having used drugs at least once (marijuana, snorted
cocaine, crack, or solvents) and themajoritywerenot habitual
or previous cigarette smokers (50% were non-smokers and 76%
were not current smokers). Sexual debut occurred at 17
years of age for 54% of the participants; the number of sexual
partners within the past year and lifetime was ‘1’ for 65% and
‘up to 4’ for 53% of the women, respectively. Approximately
20%of the participants reportedahistory ofHPV infection; 52%
reported condomuse in the last sexual intercourse. At the time
of enrollment into the cohort, 49% of the women had shownsigns of advanced immunosuppression: nadir CD4+ T-cell count
was <100 cells/mm3 for 22% and between 100 and 200 cells/
mm3 for 49%, respectively. At enrollment, 53% of the partici-
pants had already received ARV for at least 60 days, of whom
60% were receiving HAART. The median time under HAART
before enrollment was 213 days (interquartile range 113—432
days).
HC II was performed on all 634 samples, which revealed an
overall prevalence of HPV infection of 48%. Of the 306 HPV-
positive women, 287 (94%) were infected with at least one
high-risk HPV type, while 19 (6%) had only low-risk HPV types.
The overall prevalence of high-risk HPV types in this cohort
was 45% (287 out of 634). Figure 1 shows the prevalence of
HPV types for the subset of 112 participants for whom PCR
genotyping analysis was available. Among these women, 87%
had more than one HPV type detected. The HPV types most
frequently detected were 68 (47%), 58 (41%), and 39 (24%).
The HPV types most often associated with cervical squamous
intraepithelial lesions and invasive cervical cancer, HPV types
16 and 18, were detected in 23% and 13% of the samples,
respectively. HPV types 6 and 11 were each detected in less
than 2% of the women. Also within this subset of women, 14%
were infected with only one type while 16% were infected
with two, 21% with three, 19% with four, 11% with five, and
12% with more than five types.
Table 2 shows the results from the bivariate analysis using
the Poisson regression model for the estimation of the pre-
valence ratios (PR). Several demographic, behavioral, and
epidemiological characteristics were independently asso-
ciated with infection by a high-risk HPV type. An inverse
relationship was found between high-risk HPV infection and
age: women <30 years of age had a prevalence of high-risk
HPV almost 50% higher than women over 40 years of age (PR
1.5, 95% confidence interval (CI) 1.2—1.9 for age <30 years).
Being married/living with partner (PR 1.2, 95% CI 1.0—1.5),
reported drug use at any point in life (PR 1.2, 95% CI 1.0—1.4),
and earlier sexual debut (17 years of age; PR 1.2, 95% CI
1.0—1.4) were significantly associated with high-risk HPV
infection. The number of sexual partners in the previous
year (PR 1.5, 95% CI 1.1—2.1 for ‘2 or more partners’ com-
pared to ‘none’) and total lifetime sexual partners (PR 1.2,
95% CI 0.97—1.4) were also significantly associated with high-
risk HPV infection. As expected, self-reported history of prior
HPV infection was associated with detection of a current
infection (PR 1.3, 95% CI 1.1—1.5). Condom use in the last
sexual intercourse was significantly associated with high-risk
HPV infection (PR 1.3, 95% CI 1.1—1.7). In the bivariate
analysis, the variable most significantly associated with
high-risk HPV infection was the nadir CD4+ T-cell count (PR
1.6, 95% CI 1.3—2.0 for CD4+ T-cell count <100 and PR 1.4,
95% CI 1.1—1.8 for CD4+ T-cell count 100—200). Immunosup-
pression at baseline, defined as a CD4+ T-cell count
<200 cells/mm3, was also significantly associated with
high-risk HPV infection (PR 1.6, 95% CI 1.2—2.1).
Figure 2 shows that the overall HPV viral load increased, as
reflected by higher RLU ratios, as the baseline CD4+ T-cell
count decreased ( p = 0.002). No significant associations were
found between HPV infection and race/ethnicity, schooling,
income, smoking (current or ever), number of pregnancies,
and self-reported history of STDs (except HPV).
The result of multivariate modeling is shown in Table 3.
As previously stated, with two exceptions, the covariates
Table 1 Demographic, behavioral, and epidemiological
data for the 634 women enrolled in the HIV-infected cohort
of Evandro Chagas Clinical Research Institute at the Oswaldo
Cruz Foundation, Rio de Janeiro, Brazil
Characteristic n (%)
Age (years)
<30 181 (28.5)
30—40 267 (42.1)
>40 186 (29.3)
Race/ethnicity
White 295 (46.5)
Non-white 339 (53.5)
Married/living with partner
Yes 237 (37.4)
No 397 (62.6)
Schooling (years of formal education)
<5 150 (23.9)
5—8 220 (35.1)
>8 257 (41.0)
Monthly income (US Dollars) a
<75 93 (14.7)
75—300 275 (43.4)
>300 266 (42.0)
Employment status
Employed (formal or informal) 283 (44.7)
Unemployed 350 (55.3)
Ever smoked
No 230 (50.5)
Yes 225 (49.5)
Current smoker
No 343 (75.6)
Yes 111 (24.4)
Ever used drugs
No 440 (69.5)
Yes 193 (30.5)
Age at first sexual intercourse (years)
>17 290 (45.7)
17 344 (54.3)
Number of sexual partners in the previous year
None 146 (23.0)
1 414 (65.3)
2 or more 74 (11.7)
Number of lifetime sexual partners
Up to 4 334 (52.7)
5 or more 300 (47.3)
Number of pregnancies
None 54 (8.5)
1—3 376 (59.4)
4 or more 203 (32.1)
Self-reported history of STD (except HPV)
No 387 (61.6)
Yes 241 (38.4)
Self-reported history of HPV
No 349 (80.2)
Table 1 (Continued )
Characteristic n (%)
Yes 86 (19.8)
Condom use in the last sexual intercourse
No 276 (47.9)
Yes 300 (52.1)
Nadir CD4+ T-cell count (cells/mm3)
<100 105 (22.0)
100—200 234 (49.2)
200 137 (28.8)
Baseline CD4+ T-cell count (cells/mm3)
<200 129 (25.8)
200—500 234 (46.8)
500 137 (27.4)
Use of ARV therapy for at least two months before enrollment
No 295 (46.8)
Yes 336 (53.2)
Use of HAART among those in use of ARV
No 136 (40.5)
Yes 200 (59.5)
Percentages are given within the valid responses of each variable.
STD, sexually transmitted disease; HPV, human papillomavirus;
ARV, antiretroviral; HAART, highly active antiretroviral therapy.
a Conversion: US$ 1 = R$ 2.
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bivariate analysis, assuming a threshold of 0.15, were intro-
duced into the final model. The variable codifying the use of
HAART was forced into the initial model. The final multi-
variate model, comprised of five variables, highlights the
independent predictors of high-risk HPV infection. Age (<30
years of age) was associated with a 52% higher prevalence of
infection when compared to women40 years of age (PR 1.5,
95% CI 1.1—2.1). A higher prevalence of high-risk HPV infec-
tion was associated with ‘reported use of drugs at least once’
(PR 1.3, 95% CI 1.0—1.6) and ‘reported history of HPV infec-
tion’ (PR 1.2, 95% CI 0.96—1.6). ‘Reported history of HPV
infection’ was kept in the final multivariate model because of
its biological plausibility and borderline statistical signifi-
cance. Condom use in the last sexual intercourse was sig-
nificantly associated with high-risk HPV infection (PR 1.3, 95%
CI 1.1—1.7). Finally, the degree of immunosuppression prior
to enrollment within the cohort was the factor most signifi-
cantly associated with high-risk HPV infection. Women having
a nadir CD4+ T-cell count lower than 100 cells/mm3 had a
prevalence of infection 56% higher than those who were not
immunosuppressed (PR 1.6, 95% CI 1.2—2.1). A nadir CD4+ T-
cell count of 100—200 cells/mm3 was associated with a pre-
valence of infection 34% higher compared to women who
were not immunosuppressed (PR 1.3, 95% CI 1.2—2.0).
Discussion
With the introduction and availability of HAART, the spectrum
of disease in the AIDS epidemic has been shifting. It is
estimated that up to 40% of HIV-infected individuals may
develop a neoplastic lesion, including cervical cancer.17 The
Figure 1 Prevalence of HPV type for 112 HPV infected women enrolled in the HIV-infected cohort of Evandro Chagas Clinical Research
Institute at Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
76 B. Grinsztejn et al.relationship between cervical neoplasia, the end stage of
HPV-associated cervical intraepithelial lesions, and HIV
infection was identified early in the epidemic as an important
gender-specific problem.18 In this study we have assessed the
prevalence of HPV infection among the HIV-infected women
of the Evandro Chagas Clinical Research Institute cohort. Risk
factors for HPV infection were statistically assessed to better
characterize the population at greater risk of HPV infection
and, possibly, HPV derived complications.
We detected a high prevalence of HPV infection (48%) in
this cohort. This finding is in accordance with studies con-
ducted in other parts of the world using the same HPV
detection methodology.19—21 A higher prevalence of HPV
infection has been detected in Brazil and in other countries
using laboratory assays with increased sensitivity, such as
PCR.22—27 In Brazil, the prevalence of HPV among women of
unknown HIV status has been shown to be substantially lower
(14%28) than that measured in this population.
We have also detected a high overall prevalence of high-
risk HPV types (45%), and a high prevalence of high-risk
HPV types among HPV-infected women (94%). In addition,
increased HPV viral load levels were directly related to
lower baseline CD4+ T-cell counts (Figure 2). These findings
are in agreement with several studies in HIV-infected
women that detected a higher prevalence of high-risk
HPV types and of HPV co-infections, and an increased
HPV viral load in immunosuppressed women.2,6,23,25,29—31
It remains unclear whether the increased prevalence of
infection and the increased number of HPV types detected
reflect recent exposure or reactivation of prior HPV infec-
tion due to HIV induced immunosuppression.5 Our data
suggest that HIV-induced immunosuppression increases
the likelihood of detecting an HPV genital infection. Other
studies suggest that different mechanisms may be
involved, such as higher shedding of viral particles caused
by cellular changes secondary to the HIV/HPV interac-
tion,32 and higher persistence of HPV infection among
HIV-infected women facilitating diagnosis.27,31,32 Also,
higher HPV viral load among individuals with lower CD4+T-cell counts may facilitate HPV detection in this popula-
tion.5
Of the studies conducted in Brazil in HIV-infected women,
few have evaluated the association between covariates and
the prevalence of HPV infection. The knowledge of risk
factors for HPV infection among HIV-infected women iden-
tifies women at particularly high risk of HPV infection and
cervical neoplasia, who should be targeted by cervical cancer
prevention programs. This is particularly important in places
where access to cytological screening and gynecological care
is limited. Factors statistically associated with a higher pre-
valence of high-risk HPV infection are described below. Some
of these factors have been found to be associated with other
sexually transmitted diseases.13
The prevalence of genital HPV infection has typically been
shown to decrease with age.33,34 Consistent with these data,
in our study, young age was found to be a significant risk
factor for high-risk HPV infection. It has been shown that
cervical HPV infection is acquired early after sexual debut.
HPV prevalence peaks in the late teens/early adulthood and
then declines.35 Although the mechanism of the age-related
decline of HPV prevalence is not well understood, it may
reflect acquisition of cell-mediated immunity.
Total number of lifetime sexual partners was significantly
associated with high-risk HPV infection. This suggests that
the detection of HPV in HIV-infected women is a reflection of
either reactivation or persistence of pre-existing HPV infec-
tion rather than recent HPV acquisition. Other reports have
associated genital HPV with the total number of lifetime
sexual partners.33,36,37 Interestingly, in the Women’s Inter-
agency HIV Study (WIHS) and the HIV Epidemiology Research
Study (HERS), the number of male sexual partners within the
past 6 months was not associated with the prevalence of HPV
infection.25 In the WIHS cohort, 22% of sexually inactive HIV-
positive women with a CD4+ T-cell count of <200 cells/mm3
had at least one incident HPV detection.38 This is consistent
with the idea that a substantial proportion of HPV infection
detected in older women may reflect reactivation of an old
HPV infection rather than a new infection.38
Table 2 Prevalence ratios of bivariate analysis of covariates for
high-risk HPVa for the 634 women enrolled in the HIV-infected
cohort of Evandro Chagas Clinical Research Institute at the
Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
Variable PR 95% CI
Age (years)
<30 1.47 1.16—1.86d
30—40 1.29 1.02—1.62d
>40 1.00
Race/ethnicity
White 1.00
Non-white 1.01 0.85—1.19
Married/living with partner
Yes 1.21 1.00—1.45d
No 1.00
Schooling (years of formal education)
<5 0.95 0.76—1.19
5—8 1.03 0.85—1.25
>8 1.00
Monthly income (US Dollars) b
<75 0.94 0.71—1.25
75—300 1.13 0.94—1.35
>300 1.00
Ever smoked
No 1.00
Yes 1.02 0.84—1.24
Current smoker
No 1.00
Yes 1.02 0.81—1.27
Ever used drugs
No 1.00
Yes 1.19 1.00—1.42c
Age at first sexual intercourse (years)
17 1.19 1.00—1.42c
>17 1.00
Number of sexual partners in the previous year
None 1.00
1 1.26 0.99—1.59c
2 or more 1.50 1.10—2.04d
Number of lifetime sexual partners
Up to 4 1.00
5 or more 1.15 0.97—1.37c
Number of pregnancies
None 1.18 0.89—1.57
1—3 1.04 0.86—1.24
4 or more 1.00
Self-reported history of STD (except HPV)
No 1.00
Yes 1.07 0.90—1.28
Self-reported history of HPV
No 1.00
Yes 1.27 1.06—1.53d
Condom use in the last sexual intercourse
No 1.00
Table 2 (Continued )
Variable PR 95% CI
Yes 1.34 1.09—1.65d
Nadir CD4+ T-cell count (cells/mm3) ever before enrollment
<100 1.59 1.28—1.98d
100—200 1.42 1.11—1.81d
200 1.00
Baseline CD4+ T-cell count (cells/mm3) within 90 days of
enrollment
<200 1.58 1.20—2.07d
200—500 1.13 0.86—1.49
500 1.00
Use of ARV therapy for at least two months before enrollment
No 1.00
Yes 1.10 0.92—1.31
Use of HAART among those in use of ARV
No 1.00
Yes 1.14 0.89—1.45
PR, prevalence ratio; CI, confidence interval; STD, sexually trans-
mitted disease; HPV, human papillomavirus; ARV, antiretroviral;
HAART, highly active antiretroviral therapy.
aHybrid capture II results.
bConversion: US$ 1 = R$ 2.
cp-Value less than 0.15.
dp-Value less than 0.05.
HPV in HIV-infected Brazilian women 77A self-reported history of HPV infection was also an
independent predictor of HPV infection among study parti-
cipants. This finding is consistent with the reports from the
WIHS cohort.25 A history of previous exposure to HPV, as an
independent risk factor for HPV infection, suggests that HIV
infection can act as a modulating factor of the natural history
of HPV infection, which can lead to a longer persistence and
the potential development of HPV-related cervical lesions.
HPV infection was also more prevalent among women who
reported drug use at least once in their life. This finding has
been reported in other studies.30,39
In this study, use of condom in the last sexual intercourse
was a predictor of HPV infection. Although condom use is an
effective barrier against genital HIV transmission, the pro-
tective effect of condom use for other sexually transmitted
infections, including HPV, is ambiguous.40—42 A paradoxical
effect has been reported stating that condom use increases
risk of HPV infection.40,43,44 This is likely a result of an
increased probability of infection among partners with whom
condoms are used. That is, people tend to use condoms with
partners that they consider to be ‘high risk’ (e.g., new
partners, casual partners, sex workers), but not with part-
ners they consider ‘safe’ (e.g., long-term, regular partners or
spouses).
In 1991, Brazil made available ARV drugs for HIV/AIDS
patients, and since 1996, HAART has been universally avail-
able in the country. In our cohort, at the time of enrollment,
53% of the women were already using ARV, of whom almost
60% were receiving HAART. It is possible that by the time of
cohort entry, some level of immune restoration in response to
ARV had already occurred in a fraction of the women. As a
result, we chose to exclude the baseline CD4+ T-cell counts in
the multivariate modeling. In our cohort, the nadir CD4+ T-
Figure 2 HPV viral load as a function of immunosuppression as
defined by the baseline CD4+ T-cell count. (The baseline CD4+ T-
cell count was used instead of the nadir CD4+ T-cell count since
the objective is to correlate the level of immunosuppression at
enrollment with the CD4+ T-cell count at that time.).
78 B. Grinsztejn et al.cell count best reflects the level of immunodeficiency
reached by these women. Nadir CD4+ T-cell count was the
strongest independent risk factor for HPV infection in the
bivariate and multivariate analyses (Tables 2 and 3, respec-
tively). This result is consistent with the role of the immune
response in controlling HPV infection. After controlling other
factors, HPV prevalence was 56% and 34% higher among those
women with nadir CD4+ T-cell counts less than 100 cells/mm3
and between 100 and 200 cells/mm3, respectively (compared
to women with higher CD4+ T-cell counts). This result sug-
gests that as the CD4+ T-cell count declines, vigilant follow-
up of the anogenital tract, particularly with cervical cyto-
logical screening, is warranted.
In this analysis, use of ARV or HAARTwas not shown to be
associated with a protective effect for HPV infection. An
immunological mechanism may be invoked in order to inter-
pret this finding. CD4+ T-cell count reconstitution as a func-
tion of HAART does not necessarily reflect HPV-specific
immune reconstitution. However, although a protective
effect of HAART on cervical HPV infection has not been
shown, a higher rate of regression of high-grade cervical
intraepithelial neoplasia (CIN) among women on HAARTcom-
pared to those not on HAART has been observed.3
In the multivariate analysis five factors remained inde-
pendently associated with HPV infection: (a) younger age, (b)
drug use ever, (c) self-reported history of HPV infection, (d)
condom use in the last sexual intercourse, and (e) immuno-
suppression. Of note, the most significant factor associated
with HPV infection was advanced immunosuppression as
measured by the nadir CD4+ T-cell count. Our results support
the association of immunosuppression as an important deter-
minant of HPV infection. Perhaps HIV acts as a modulating
factor of the natural history of HPV infection, leading to a
longer persistence and greater production of virus particles31(and thus allowing detection). Actually the longer persis-
tence and greater production of virus might lead to greater
infectivity. Yet this effect would appear to persist well
beyond the period of low CD4+ T-cell count, when HIV is
controlled and CD4+ T-cell counts rise, and HPV is still
detected. This may contribute to the higher risk of develop-
ment of HPV related cervical lesions in the HIV-infected
subgroup.
Of note, the use of newly available preventive mea-
sures, specifically the HPV vaccines targeting types 16 and
18, may help mitigate the impact of HIV on cervical cancer
in developing countries. In settings where cytologic screen-
ing remains insufficient, prevention of HPV infection might
be the best strategy. HPV prevalence studies such as this
one are fundamental for planning HPV immunization pro-
grams for HIV-infected women. The relatively low preva-
lence of HPV types 16 and 18, the higher prevalence of
other high-risk HPV types, and the frequent detection of
multiple HPV types in our study should be carefully taken
into account when considering immunization strategies for
HIV-infected women in our setting. Currently, HPV types 58,
68, and 39 are not included in the tetravalent vaccine and
there are very limited data available considering cross-
protection to these types in immunized subjects.45 HPV
58 is highly prevalent in South American women, indepen-
dent of cytological classification or HIV status.46—48 While
the oncogenic potential of HPV 39 is well-established, that
of HPV 68 remains undetermined, being both included in
the high-risk group and belonging to the species 7 of the
genus alpha-papillomavirus, together with HPV 18.49 HPV
68 appears to be more prevalent in Brazilian HIV-infected
women than in other populations, including HIV-infected
women from other countries. Our results suggest that the
investigation of prevalence and clearance of HPV types 58,
68, and 39 is of importance in vaccine trials among Brazilian
HIV-infected women. Increased HPV prevention strategies
are needed particularly in the HIV infected population,
where the incidence of HPV-related lesions may increase
due to the extended survival of HIV patients under HAART
treatment.
This study has some limitations particularly as regards the
fact that the cross-sectional analysis of the cohort only allows
detection of factors associated with prevalence of HPV infec-
tion. Currently, a longitudinal study of the cohort is underway
to evaluate if the HPV infections here described are transi-
tory or persistent, bringing further consistency to these
results. Also, HPV typing results were restricted to a subset
of patients and studies with larger series of patients with HPV
typing results are needed.
In summary, the high prevalence of HPV infection,
particularly of high-risk HPV types, in HIV-infected women,
is worrisome given the still limited access to cytological
screening and gynecological care. Widespread availability
of HAART adds further complexity to the HIV—HPV co-
infection problem. Increased patient survival rates may
allow for cervical lesions to further evolve, resulting in an
increased risk of developing a neoplasia. Current data on
the effect of HAART on the natural history of CIN are
mixed, but it seems clear that if there are beneficial
effects, these are relatively modest. There is still much
to be learned with respect to the impact of HAART on HPV
infection and associated cervical diseases. HIV-infected
Table 3 Prevalence ratios (PR) in multivariate analysis for
factors independently associated with high-risk HPV for the
634 women enrolled in the HIV-infected cohort of Evandro
Chagas Clinical Research Institute at the Oswaldo Cruz Founda-
tion, Rio de Janeiro, Brazil. Parameters of the Poisson regression
model were estimated by maximum likelihood
Variable Initial model a Final model
PR 95% CI PR 95% CI
Age (years)
<30 1.47 0.99—2.17c 1.52 1.08—2.12c
30—40 1.11 0.77—1.60 0.86—1.65
>40 1.00 1.19
Married/living with partner
Yes 1.05 0.78—1.41
No 1.00
Ever used drugs
No 1.00 1.00
Yes 1.20 0.92—1.58 1.28 1.02—1.60c
Age at first sexual intercourse (years)
17 1.15 0.85—1.55
>17 1.00
Number of lifetime sexual partners
Up to 4 1.00
5 or more 1.23 0.92—1.63
Self reported history of HPV
No 1.00 1.00
Yes 1.16 0.85—1.59 1.23 0.96—1.59
Condom use in the last sexual intercourse
No 1.00 1.00
Yes 1.18 0.89—1.57 1.34 1.06—1.70c
Nadir CD4+ T-cell count (cells/mm3)
<100 1.46 1.05—2.02c 1.56 1.18—2.06d
100—200 1.45 1.05—2.00c 1.34 1.16—1.96d
200 1.00 1.00
Use of highly active antiretroviral therapyb
No 1.00
Yes 1.09 0.82—1.44
PR, prevalence ratio; CI, confidence interval; HPV, human papillo-
mavirus.
aCovariates entering initial full model were selected with a 0.15
cutoff value in bivariate analysis. Exceptions are ‘number of partners
in the previous year’ and ‘baseline CD4+ T-cell count’ which were not
included. ‘Use of highly active antiretroviral therapy’ was forced into
initial model. Variable removal was guided by effect size and sta-
tistical significance using the 0.05 threshold.
bFor those in use of ARV therapy for at least 2 months prior to
enrollment.
cp-Value less than 0.05.
dp-Value less than 0.01.
HPV in HIV-infected Brazilian women 79women should be among those prioritized in screening
programs. Focus should rest on the youngest, with
advanced immunosuppression, and history of HPV and of
drug use. It is urgent that public health officials be aware
of the potential impact of the HIV epidemic on cervical
cancer.Acknowledgments
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